Last reviewed · How we verify
contrast agent (iopromide)
Iopromide is a non-ionic iodinated contrast agent that increases radiodensity in blood vessels and tissues to enhance visualization during radiographic imaging procedures.
Iopromide is a non-ionic iodinated contrast agent that increases radiodensity in blood vessels and tissues to enhance visualization during radiographic imaging procedures. Used for Contrast enhancement for angiography and vascular imaging, Contrast enhancement for computed tomography (CT) imaging, Contrast enhancement for urography and other radiographic procedures.
At a glance
| Generic name | contrast agent (iopromide) |
|---|---|
| Sponsor | Seoul National University Bundang Hospital |
| Drug class | Non-ionic iodinated contrast agent |
| Modality | Small molecule |
| Therapeutic area | Diagnostic Imaging |
| Phase | FDA-approved |
Mechanism of action
Iopromide contains iodine atoms that absorb X-rays, creating contrast between different tissue densities on radiographic images. It is administered intravenously and distributes through the vasculature and extracellular space, allowing enhanced visualization of blood vessels, organs, and tissues during angiography, CT, and other imaging procedures. As a non-ionic contrast agent, it has lower osmolality than ionic agents, reducing the risk of adverse reactions.
Approved indications
- Contrast enhancement for angiography and vascular imaging
- Contrast enhancement for computed tomography (CT) imaging
- Contrast enhancement for urography and other radiographic procedures
Common side effects
- Contrast-induced nephropathy
- Allergic reaction
- Nausea and vomiting
- Flushing and warmth sensation
- Hypersensitivity reactions
Key clinical trials
- Low-acid Contrast Media for Preventing Post ERCP Pancreatitis
- Clinical Effectiveness of CEM in Diagnosis of Additional Findings at Preoperative Breast Magnetic Resonance Imaging (NA)
- Paclitaxel-coated Balloon for Treatment of De-novo Non-complex Coronary Artery Lesions (NA)
- A Study, Called UV Population, to Learn More About the Safety of the Study Drug Ultravist, Which is Given to Get Clearer X-ray Pictures, in People of Different Sexes, Races, and From Different Countries/Regions
- Preoperative Assessment of Pathological Nipple Discharge With Delayed Ductal Imaging of Contrast-enhanced Mammography (NA)
- Multislice CT Angiography of Coronary Bifurcations and Outcomes After Intervention (NA)
- Serum Thyroid Function After Iodinated Contrast Administration
- Short-Term Exposure to Lipophilic Anti-proliferative Drugs Delivered by Angiographic Contrast Media (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- contrast agent (iopromide) CI brief — competitive landscape report
- contrast agent (iopromide) updates RSS · CI watch RSS
- Seoul National University Bundang Hospital portfolio CI